Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

The Clorox Company (CLX), Colgate-Palmolive Company (CL): This Stock Is Cleaning Up Nicely

Page 1 of 2

One of the less-talked about consumer-stable stocks is The Clorox Company (NYSE:CLX), however it could easily be the best. This $11-billion market cap producer of household cleaning and specialty food products is mostly overshadowed by the likes of The Procter & Gamble Company (NYSE:PG) and Colgate-Palmolive Company (NYSE:CL), both with market caps in excess of $50 billion. 

The Clorox CompanyBut the beauty about The Clorox Company (NYSE:CLX) is that it pays one of the highest dividend yields in the industry at 3.3% and has a low beta of 0.4. Billionaire Carl Icahn was an activist in the stock back in 2011. Icahn was looking to kick out some of Clorox’s directors. Icahn abandoned his campaign, and since the beginning of 2012, the stock has performed in line with the S&P 500, both being up around 33%. I think Clorox could finally be poised for a breakout.

The Clorox Company (NYSE:CLX) gets around 80% of sales from the U.S., with liquid bleach representing about 13% of total net sales, trash bags 13%, and charcoal 11%. This product portfolio of consumer stables helps the company sustain economic swings and downturns, hence the low beta.

The consumer-products company is looking to expand beyond the U.S.; this includes focusing on Asia and the Middle East. The Clorox Company (NYSE:CLX) also plans to continue looking to acquisitions to help grow sales, where it recently bought up Aplicare and HealthLink, both in the health and wellness industry.

Toothpaste giant

Colgate-Palmolive Company (NYSE:CL) is one of the top consumer-products companies, offering products to more than 200 countries. It is expected to see sales up only 3% in 2013, with 6% organic growth expected to be driven by Colgate’s exposure to fast growing international markets.

Unlike The Clorox Company (NYSE:CLX), which gets 80% of sales from the U.S., Colgate-Palmolive Company (NYSE:CL) gets 80% of sales from outside the U.S. and 50% specifically from the emerging markets. Its oral- and personal-care products account for 87% of sales; these items include toothbrushes, toothpaste, soaps, shampoos, deodorants, Palmolive and Ajax soaps.

Last month, Colgate-Palmolive Company (NYSE:CL) lowered its 2013 earnings expectations due to continued pressure in international markets, namely Latin America. The big issue here is the devaluation of the Venezuelan bolivar. Last quarter, this contributed to a 1.5% sales decrease in Latin America. New guidance includes EPS growth expectations of 4.5% to 5.5% for 2013 — down one percentage point from prior guidance.

Fellow small timer

Church & Dwight Co., Inc. (NYSE:CHD) is another smaller consumer-products company, like The Clorox Company (NYSE:CLX), with an $8.7 billion market cap. Church & Dwight pays a 1.8% dividend yield and also has a low beta at 0.4. The company is a manufacturer of various household, personal care and specialty products, which include Arm & Hammer, Orajel and Trojan. Church & Dwight’s major segment is consumer domestic, making up nearly 75% of sales.

Back in 2012, Chruch snatched up Avid Health for $650 million. Avid is the leading gummy-form maker of vitamins and supplements, with major brands VITAFUSION and L’IL CRITTERS. Church & Dwight Co., Inc. (NYSE:CHD) CEO notes that..

“The acquisition of Avid’s gummy vitamins business represents a great addition to our existing portfolio and brings to our company a new growth platform in one of the fastest-growing segments of the attractive vitamin/mineral / supplement category. It is also consistent with our strategy of strengthening our business by adding [number-one] or [number-two] brands in areas of high-growth potential.”

Sales are expected to be up 12% in 2013, where the Avid Health deal is expected to be a key driver. Some 8% of the 2013 sales growth is expected to be driven by Avid.

Page 1 of 2
Loading Comments...